PMID- 34766136
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211204
IS  - 2688-2663 (Electronic)
IS  - 2688-2663 (Linking)
VI  - 2
IP  - 1
DP  - 2021 Mar
TI  - Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different 
      tumors.
PG  - 60-68
LID - 10.1002/mco2.61 [doi]
AB  - PD-1/PD-L1 (programmed cell death-1 and programmed death-ligand 1) inhibitors 
      utilization in neoadjuvant therapy has been assessed in tumors. This study 
      focused on the clinical benefits of neoadjuvant anti-PD-1/PD-L1 therapy. A 
      comprehensive search was conducted in electronic databases to identify eligible 
      studies. Major response rate (MRR) and complete response rate (CRR) were pooled 
      in this analysis to assess the efficacy of neoadjuvant anti-PD-1/PD-L1 
      utilization, all grades and high-grade adverse events (AEs) were pooled to 
      evaluate its safety. Twenty studies were included in this meta-analysis, with 828 
      patients suffering from different tumors. The pooled CRR of triple-negative 
      breast cancer was 0.569 (95% CI 0.514, 0.624, I (2) = 0%) and the pooled MRR of 
      lung cancer was 0.471 (95% CI 0.267, 0.575, I (2) = 0%). The most frequent 
      adverse event was fatigue (0.272 95% CI 0.171, 0.402, I (2) = 87%), and the most 
      common high-grade adverse event was febrile neutropenia (0.084 95% CI 0.063, 
      0.112, I (2) = 85%). In conclusion, neoadjuvant anti-PD-1/PD-L1 therapy received 
      satisfactory clinical results in these tumors included.
CI  - (c) 2021 The Authors. MedComm published by Sichuan International Medical Exchange & 
      Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
FAU - Li, Zhiyang
AU  - Li Z
AD  - Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital 
      Sichuan University Chengdu Sichuan China.
AD  - West China Hospital, West China School of Medicine Sichuan University Chengdu 
      Sichuan China.
FAU - Wu, Xin
AU  - Wu X
AD  - Head and Neck Carcinoma Department, Radiation Oncology Department, Cancer Center 
      West China Hospital Chengdu Sichuan China.
FAU - Zhao, Yanjie
AU  - Zhao Y
AD  - Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital 
      Sichuan University Chengdu Sichuan China.
AD  - West China Hospital, West China School of Medicine Sichuan University Chengdu 
      Sichuan China.
FAU - Xiao, Yinan
AU  - Xiao Y
AD  - Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital 
      Sichuan University Chengdu Sichuan China.
AD  - State Key Laboratory of Biotherapy Department of Biotherapy, West China Hospital, 
      Cancer Center Sichuan University Chengdu Sichuan China.
FAU - Zhao, Yunuo
AU  - Zhao Y
AD  - Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital 
      Sichuan University Chengdu Sichuan China.
AD  - State Key Laboratory of Biotherapy Department of Biotherapy, West China Hospital, 
      Cancer Center Sichuan University Chengdu Sichuan China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital 
      Sichuan University Chengdu Sichuan China.
AD  - West China Hospital, West China School of Medicine Sichuan University Chengdu 
      Sichuan China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital 
      Sichuan University Chengdu Sichuan China.
AD  - West China Hospital, West China School of Medicine Sichuan University Chengdu 
      Sichuan China.
FAU - Sha, Fushen
AU  - Sha F
AD  - Department of Internal Medicine State University of New York: Downstate Medical 
      Center Brooklyn New York USA.
FAU - Wang, Yating
AU  - Wang Y
AD  - Department of Internal Medicine Louis A. Weiss Memorial Hospital Chicago Illinois 
      USA.
FAU - Deng, Lei
AU  - Deng L
AD  - Jacobi Medical Center Albert Einstein College of Medicine, Bronx New York New 
      York USA.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital 
      Sichuan University Chengdu Sichuan China.
AD  - State Key Laboratory of Biotherapy Department of Biotherapy, West China Hospital, 
      Cancer Center Sichuan University Chengdu Sichuan China.
LA  - eng
PT  - Journal Article
DEP - 20210311
PL  - China
TA  - MedComm (2020)
JT  - MedComm
JID - 101769925
PMC - PMC8491227
OTO - NOTNLM
OT  - PD-1/PD-L1 inhibitors
OT  - atezolizumab
OT  - lung cancer
OT  - neoadjuavant therapy
OT  - triple-negative breast cancer
COIS- The authors declare that there is no conflict of interest.
EDAT- 2021/11/13 06:00
MHDA- 2021/11/13 06:01
PMCR- 2021/03/11
CRDT- 2021/11/12 07:14
PHST- 2020/05/08 00:00 [received]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2021/11/12 07:14 [entrez]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2021/11/13 06:01 [medline]
PHST- 2021/03/11 00:00 [pmc-release]
AID - MCO261 [pii]
AID - 10.1002/mco2.61 [doi]
PST - epublish
SO  - MedComm (2020). 2021 Mar 11;2(1):60-68. doi: 10.1002/mco2.61. eCollection 2021 
      Mar.